Detection of HPV infection in head and neck cancers: Promise and pitfalls in the last ten years: A meta-analysis

CAROLIN GÖTZ , CLARA BISCHOF, KLAUS-DIETRICH WOLFF and ANDREAS KOLK

Department of Oral and Maxillofacial Surgery, Technical University of Munich, Klinikum Rechts der Isar, D-81675 Munich, Germany

Received October 27, 2017; Accepted August 9, 2018

DOI: 10.3892/mco.2018.1749

Abstract. The current controversial discussion on the disease-specific survival of patients with human papillomavirus (HPV)-positive (+) and -negative (-) squamous cell carcinoma (SCC) of the head neck region was the motivation for the present meta-analysis. Different detection methods for HPV are available, though these often lack sensitivity. As a consequence, there may be false interpretation of HPV positivity. A bias concerning HPV status and therefore also survival rates is serving a non-durable relevance in the discussion of tailored therapies. A literature search was performed via the online database PubMed/NCBI, and data extraction and statistical analysis were conducted. A total of 139 studies published between 2004 and 2014 were evaluated in the present meta-analysis. The HPV detection methods, patient characteristics, tumor localizations and stages, as well as (neo-) adjuvant therapies and survival times were analyzed. The average incidence rates of HPV + patients with oropharyngeal tumors were higher than those of patients with cancers of other regions of the head and neck. Upon evaluating the results of different detection methods no significant differences were identified. We have compared the HPV incidence rates of each detection method, when studies have used more than one. Regarding overall survival, the pooled adjusted hazard ratio (HR) for oropharyngeal SCC was 0.31 [95% confidence interval (CI)=0.27-0.36]. Unfortunately, only 3 equivalent studies were available on nonoropharyngeal tumors, for which the pooled adjusted HR was 1 (95% CI=0.73-1.36). Overall, the evaluation demonstrated that the survival rates reported in numerous studies were not evaluated multifactorially and important confounders were excluded from the statistics. The HPV detection methods used were often not sufficient in representing HPV positivity. In addition, oropharyngeal and oral SCCs were assessed together in the localization. The widely differing number of HPV + patients in each of the various studies may be explained by insufficient detection methods and by a lack of localization distinction. The considerations of a tailored therapy according to HPV status should be rejected based on the present information. The previously published studies should be read critically and do not represent a basis for therapeutic decisions.

Introduction

Head and neck cancer (HNC) is reportedly the sixth most common cancer diagnosed worldwide; in 2008, ~633,000 new cases were diagnosed, and ~355,000 cases resulted in mortality (1). HNC encompasses all malignant tumors of the upper aerodigestive tract, which begins at the vermilion border of the lips and extends to the beginning of the esophagus. Approximately 90% of malignant neoplasms of the head and neck are squamous cell carcinomas (SCCs), while only just >5% are adenocarcinomas (2). The incidence rate varies according to geographic region and associated risk factors of differing severity. In recent decades, a declining incidence rate, particularly for the cancers of the oral cavity, hypopharynx and larynx, has been observed as an effect of reduced tobacco consumption in industrialized countries. However, in contrast, there has been a rapid increase in the incidence rate of oropharyngeal cancers, particularly of those of the tonsils and base of the tongue, which have been associated with human papillomavirus (HPV) (3,4). In 1983, HPV was first reported in association with head and neck SCC (HNSCC) (5). The International Agency for Research on Cancer officially recognized HPV-16 infection as a risk factor for oropharyngeal SCC (OPSCC) in 2007 (6). In recent decades, the number of oropharyngeal cancers caused by HPV has risen sharply; From 1988 to 2004, it increased in the US by ≥225% (7). But not only in North America, also in Europe this observation was found (8,9). Of the 100 cancers of the pharynx, 40 are assumed to be associated with HPV (2). HPV-associated HNSCCs occur in different populations from those with cancers induced by noxious agents, and different pathogenic processes underlie their oncogenesis. In the literature, a notable discordance exists among individual studies of HPV-associated HNSCC. Estimates of the incidence rate of HPV-associated tumors also differ greatly. Furthermore, the majority of studies conclude...
that patients with HPV-associated HNSCC have a survival advantage. An important question regarding the selection of a therapeutic approach in the future is whether treatment that is less intense will be sufficient for HPV-associated tumors.

The objectives of the present study were to improve current understanding concerning: The incidence rate of HPV-associated tumors; the most reliable detection methods; and the survival probability of HPV+ patients.

Materials and methods

Search strategy. The meta-analysis was conducted according to the guidelines of the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (10,11). For an online literature search, the PubMed database was used. To identify the primary studies, the following terms were combined: ‘HPV’ and ‘HNSCC’, ‘oral cavity’, ‘OPSCC’, ‘oropharyngeal’ or ‘tonsil’ and ‘overall survival’, ‘disease-specific survival’ or ‘treatment modalities’.

Study eligibility and data extraction. The following conditions were defined for the incorporation of studies into the meta-analysis: The object of interest had to be a patient diagnosed with HNSCC; each study had to include at least 50 patients (two exceptions - there have been ≥50 patients, but only 42 respectively 49 were available for HPV testing. These two studies were included because they seemed to be very useful, due to the fact both evaluated many parameters and also considered the kind of treatment.); HPV detection had to be conducted and explained; and the survival rates had to be described and separated into HPV+/HPV− groups. Reviews and previous meta-analyses were not eligible. The publication was not included if it was more than 10 years old (two exceptions) and if it was not written in German or English. Additionally, the publication had to be available as full text. The selected studies were analyzed with respect to the following parameters: Number of patients, HPV detection method and the number of HPV+/HPV− test results, HPV subtypes, tumor localization, treatment, mean age of HPV+/HPV− patients at the time of diagnosis, alcohol consumption of HPV+/HPV− patients, tobacco use of HPV+/HPV− patients, sex of HPV+/HPV− patients, tumor, node and metastasis (TNM) stage, country and outcome. The extracted data were collected in an Excel spreadsheet.

Statistical analysis. In the statistical evaluation, the respective minima, maxima, means and medians were determined for all extracted data sets of the above-mentioned criteria. The statistical analysis of the data to compare the detection methods and the data on the supposed survival advantage was carried out with the support of the staff of the Institute of Medical Statistics and Epidemiology of the Technical University of Munich.

For the comparison of the different detection methods the ‘Random-Effect’ model was used and the Risk Difference (RD) with the 95% CI was calculated. After the heterogeneity test, also for the statistical evaluation of the supposed survival advantage, the ‘Random-Effect’ model was used. And by using the published hazard ratios (HR) and their 95% confidence interval (CI) the pooled HR for overall survival (OS) was calculated. For data collection, statistical analysis and the preparation of tables and charts, Microsoft Excel 2011 (Microsoft Corporation, Redmond, WA, USA) and R packages (cran.r-project.org/) were used.

Results

Literature search results. The literature search via PubMed yielded a total of 987 hits. The flow diagram in Fig. 1 illustrates how a final of 139 publications were selected. All abstracts were read to identify useful publications, and duplicates were rejected. In total, 459 publications, which were perceived as helpful, were read as full text. Among the sources of these publications, two further studies (>10 years) were identified to be useful and included in the present meta-analysis. The relevant data were extracted and transferred to an Excel spreadsheet. In 139 publications out of the 461 studies, including a total of 21,774 patients, fulfilled the final criteria. Of these studies, 80 were concerned solely with OPSCC (7,12-90), 13 with oral SCC (OSCC) (91-103) and 31 with both OPSCC and OSCC (104-134); 15 studies provided results on HNSCC in general (135-149).

HPV prevalence. The average percentage of patients tested as HPV+ estimated from all included studies in the meta-analysis was 42.62% [95% CI=0.39-0.46]. The mean incidence rate of the 80 OPSCC studies (12,662 patients, 6,383 HPV+) was 49.85% (95% CI=0.45-0.54). By contrast, for the 13 studies on OSCC, the mean incidence rate was 27.39% (95% CI=0.18-0.36). In a further analysis, anatomic regions were divided more specifically. As the anatomical localization of the oropharynx is of special interest according to HPV positivity, this region was further divided into: Base of the tongue, tonsils and neither of these two locations [listed as other oropharyngeal SCC (OOPSCC) in Table I]. The average incidence rate of HPV+ patients with OPSCC was 50.47% (95% CI=0.47-0.54). Notably, cancers of the base of the tongue, with an average incidence of HPV+ patients of 48.61% (95% CI=0.42-0.56), and of the tonsils, with an average incidence of HPV+ patients of 55.32% (95% CI=0.50-0.61), exhibited a relatively high association with HPV infection in particular. By contrast, oropharyngeal cancer, classified as being outside of these two regions, tested as HPV+ to a much lower extent, with an average
incidence of HPV positivity of 26.39% (95% CI=0.22-0.31). The average incidence rates of HPV+ patients with tumors of other head and neck regions excluding OPSCCs were generally below those for oropharyngeal tumors: For OSCC, 24.14% (95% CI=0.18-0.30), for laryngeal cancer, 20.61% (95% CI=0.14-0.27) and for hypopharyngeal cancer, 22.18% (95% CI=0.14-0.31). For HNSCC, the average incidence of HPV positivity was 32.93% (95% CI=0.27-0.39; Table I).

**HPV detection.** Of the studies, 95 involved polymerase chain reaction (PCR), 80 used p16 immunohistochemistry (IHC) and 30 studies employed *in situ* hybridization (ISH). A total of 79 studies determined HPV status with one detection method, while 60 studies used two, or all three, of the above methods. Evaluation of the different results regarding the incidence rates, if studies have used multiple detection methods, revealed no significant difference between PCR and IHC, ISH and PCR, and IHC and ISH (Fig. 2A-C).

**HPV subtypes.** A total of 80 studies (11,455 patients) provided information on the HPV subtypes. Among the 4,086 patients that tested HPV+, the two high-risk types HPV16 and 18 were the most frequently detected subtypes. In OPSCC (44 studies), HPV16 was detected on average in 90.55% (95% CI=0.87-0.94) of cases, and HPV18 was responsible for the infection on average in 8.10% (95% CI=0.05-0.11) of cases. Among the HPV-associated OSCC cases (10 studies), HPV16 and 18 were detected on average in 69.66% (95% CI=0.52-0.87) and 26% (95% CI=0.19-0.33) of the cases, respectively.

**Associations with HPV profile.** Data regarding other risk factors (age, TNM status, alcohol and tobacco consumption, sex) and differences between HPV+/− cases are summarized in Fig. 3. The most interesting finding was, that HPV+ patients with OPSCC were often described to be younger than HPV− patients, also the mean age was lower for HPV+ patients with OPSCC (56.5 vs. 60.8 years). But this fact could not be observed for HPV+/− patients with OSCC. Distribution of the studies according to the various countries and the mean incidence rates for OPSCC according to country are also given in Fig. 3.

**HPV and patient survival.** In the 135 studies providing information on patient survival, 94 reported an improved outcome for patients who tested HPV+, 5 documented a poorer survival rate, 25 could not detect any significant difference, and 11 reported a higher probability of survival only with HPV+ oropharyngeal tumors. Out of the 135 studies, 77 focused on oropharyngeal tumors with information on survival; 67 of these reported of an improved outcome in HPV+ patients, and 10 could not detect a significant difference. Of the 12 studies on OSCC with data on survival rates, 3 reported an improved outcome in HPV+ patients, 3 a poorer outcome, and 6 could not detect a significant difference. The data on the probability of survival were described in various formats, with the largest amount of comparable data being available for overall survival. The pooled adjusted hazard ratio (HR) for OPSCC was 0.31 (95% CI=0.27-0.36). Unfortunately, only 3 equivalent studies were available for nonoropharyngeal tumors, for which the pooled adjusted HR was 1 (95% CI=0.73-1.36, Fig. 4A and B).

**Discussion**

In the literature, the way in which prevalence rates of HPV-associated HNSCC are described varies greatly, with the main variant factors being insufficient description and fractionation of anatomical localizations, different risk factors (attributable to the time-point and the place of study), and non-uniform detection methods. In the present meta-analysis, the average incidence rate of HPV-associated
HNSCC was 42.62%. In a similar meta-analysis of 60 studies (5,046 patients), the average incidence rate was 25.9% (95% CI=0.25-0.27) (150). Another meta-analysis of 34 studies (5,681 patients) reported that 21.95% (95% CI=0.21-0.23) of HNSCCs were associated with HPV (151). The significantly higher incidence rate in the present analysis may be attributable to i) more than half of the included studies (80 studies, 12,662 patients) only investigating OPSCC, which is known to be more frequently associated with HPV (150); ii) studies older than 10 years not being included. Analysis of the 5% of studies with the highest/lowest incidence rates of HPV-associated HNSCC revealed notable similarities: In contrast to the studies with low incidence rates, most studies with high incidence rates were from North America and involved exclusively OPSCC (15,28,31,46,49,54,79,94,97,100,112,120,136,140). The average prevalence rate in the 110 studies (14,230 patients) that provided data on tumors of the oropharynx was 50.47%; in the two meta-analyses mentioned above, the average incidence rate of HPV-associated OPSCC was 35.6% (95% CI=0.33-0.39) (150) and 41% (95% CI=0.38-0.44), respectively (151). Again, the different time periods over which the studies were conducted may be responsible for the observed differences. Many studies have reported a dramatic increase in the incidence of HPV-associated OPSCC in recent decades (8,9). However, even among the HPV-associated OPSCC cases, a relatively high level of variation exists in incidence rate (minimum: 11.54%, maximum: 89.20%) (28,49). Furthermore, analysis of the 5% of OPSCC studies with the highest/lowest incidence rates of HPV-association determined some similarities: All of the 5% of studies with the highest incidence rates were conducted in North America, whereas none of the studies with the lowest incidence rates was conducted in North America (15,22,28,31,41,49,54,73). The studies with the low incidence rates of HPV-associated HNSCC mentioned the different geographic regions (41,73), the higher prevalence of ‘classic’ risk factors and therefore a lower HPV prevalence (22,41,73), and the data collection over many years (28,73) as possible causes of the low incidence rates of HPV-associated HNSCC. In the present analysis, OPSCCs were further divided into groups. Notably, a significantly higher HPV association for cancers of the tonsils and base of the tongue was observed, in contrast to cancers of other oropharyngeal regions. The average incidence rate of HPV-associated tumors (3,550 patients) of the 40 studies on OSCC was 24.14%, and therefore was similar to that determined in the meta-analysis by Kreimer: 23.5% (95% CI=0.22-0.25) (150). The current meta-analysis highlights the importance of a detailed description and distinction of the relevant anatomical localizations, since different HPV infection rates are obvious (8,52,53). As another factor, the time of the study appears to influence the HPV incidence rate (8,9); this may be explained by the significant decrease in smoking populations over the past decades (152). Due to the elimination of ‘classic risk factors’, including smoking and alcohol abuse, the number of cancers associated with other possible triggers increases. However, an increased HPV prevalence is also likely to serve a role; this may be attributable to changes in sexual practices and potential transmission via oral sex (24).

The lack of uniform standards for HPV detection makes it difficult to compare individual studies. Each detection method has its own advantages and disadvantages: In addition to sensitivity and specificity, the type of histological specimen, financial aspects, time available, and personal and equipment resources affect the choice of detection. Due to the various
advantages and disadvantages, the most reliable HPV detection method may be a combined approach that establishes both an accurate result and a cost- and time-effective test method; for instance, the high sensitivity method of p16 IHC may be combined with the high specificity method of PCR and a chip system as described previously (153). The current analysis

| HPV subtypes                  | Number of studies | Number of patients | Patients HPV+ | Patients HPV-16 | Patients HPV-18 | Average HPV-16 | Average HPV-18 |
|-------------------------------|-------------------|-------------------|---------------|----------------|----------------|----------------|----------------|
| All studies                   | 80                | 11,455            | 4,086         | 3,583          | 169            | 87.32%         | 11.65%         |
| OPSCC                         | 44                | 6,791             | 2,707         | 2,478          | 69             | 90.55%         | 8.10%          |
| OSCC                          | 10                | 1,533             | 384           | 229            | 71             | 69.66%         | 26.00%         |

| Age                           | Number of studies | Number of patients | HPV+ younger | HPV+ older | n.s.           |
|-------------------------------|-------------------|-------------------|--------------|------------|----------------|
| All studies                   | 99                | 17,977            | 43           | 4          | 52             |
| OPSCC                         | 60                | 11,591            | 32           | 2          | 26             |
| OSCC                          | 7                 | 1,008             | 0            | 0          | 7              |

| Tumor stage                   | Number of studies | Number of patients | Mean age HPV+ | Mean age HPV- | n.s.           |
|-------------------------------|-------------------|-------------------|---------------|--------------|----------------|
| All studies                   | 66                | 11,633            | 57.4          | 61.1        | 59.4           |
| OPSCC                         | 46                | 8,261             | 56.5          | 60.8        |                |
| OSCC                          | 3                 | 521               | 61.5          | 59.4        |                |

| Alcohol                       | Number of studies | Number of patients | Patients HPV+ | Patients HPV- | Alc HP+ | Alc HP- | Alc HPV+ | Alc HPV- |
|-------------------------------|-------------------|-------------------|---------------|-------------|--------|--------|---------|--------|
| All studies                   | 55                | 8,084             | 3,640         | 4,444       | 1,879  | 2,894  | 52.60%  | 62.70%  |
| OPSCC                         | 32                | 4,884             | 2,772         | 2,112       | 1,310  | 1,273  | 43.74%  | 59.26%  |
| OSCC                          | 7                 | 671               | 234           | 437         | 150    | 238    | 62.34%  | 58.29%  |

| Smoking                       | Number of studies | Number of patients | Patients HPV+ | Patients HPV- | Tobacco HP+ | Tobacco HP- | Tobacco HPV+ | Tobacco HPV- |
|-------------------------------|-------------------|-------------------|---------------|-------------|------------|------------|-------------|-------------|
| All studies                   | 74                | 11,029            | 5,218         | 5,811       | 3,168     | 4,533      | 61.84%      | 76.65%      |
| OPSCC                         | 45                | 7,445             | 4,205         | 3,240       | 2,469     | 2,538      | 57.87%      | 78.65%      |
| OSCC                          | 8                 | 779               | 245           | 534         | 167       | 317        | 62.03%      | 60.88%      |

| Gender                        | Number of studies | Number of patients | Patients HPV+ | Patients HPV- | Female HP+ | Female HP- | Male HP+ | Male HP- |
|-------------------------------|-------------------|-------------------|---------------|-------------|-----------|-----------|---------|---------|
| All studies                   | 92                | 14,309            | 6,309         | 8,000       | 1,223     | 1,626     | 5,075   | 6,233   |
| OPSCC                         | 58                | 9,161             | 4,934         | 4,227       | 936       | 809       | 3,998   | 3,342   |
| OSCC                          | 10                | 1,114             | 343           | 771         | 75        | 168       | 267     | 525     |

| Countries                     | Number of studies | Number of patients | Patients HPV+ | Mean incidence rate |
|-------------------------------|-------------------|-------------------|---------------|---------------------|
| OPSCC                         | 39                | 5,891             | 2,686         | 43.08%              |
| North America                 | 28                | 4,577             | 2,716         | 52.07%              |
| Asia                          | 14                | 1,678             | 661           | 43.64%              |

Figure 3. Data regarding HPV risk factors (Bischof C: PhD Thesis, in prep). Age: The upper panel summarizes data without detailed age information (only HPV+ patients are older/younger, no significant difference), the lower panel of the data summarizes detailed age information. Alcohol: The number of patients who described themselves as regular alcohol consumers. Smoking: The number of patients who described themselves as regular tobacco consumers. Data are presented as the n number of patients and/or the mean percentage. HPV, human papillomavirus; n.s., not significant; TNM, tumor-node-metastasis; OPSCC, oropharyngeal squamous cell carcinoma; OSCC, oral squamous cell carcinoma.
compared the results of the various detection methods, but no significant difference was observed. There is an urgent need for uniform standards regarding the HPV test procedure. However, the test method combination described above must first be confirmed as sufficiently accurate. Furthermore, the potential association between viral biological activity/integration into the host genome/higher viral load and higher survival rate must be clarified.

HPV16 and 18 were the most commonly detected subtypes (11,455 patients in 80 studies on subtype), with this result being consistent with other studies (150,151). Notably, HPV16 was more common in OPSCC than in OSCC (90.55 vs. 69.66%), and HPV18 was more often detected in OSCC than in OPSCC (11,455 patients in 80 studies on subtype), with this result being consistent with other studies (150,151). Notably, HPV16 was more common in OPSCC than in OSCC (90.55 vs. 69.66%), and HPV18 was more often detected in OSCC than in OPSCC (26.00 vs. 8.10%). These observations have previously been described, for example, the lower expression of p16 found in OSCC (155). Among the above-mentioned five studies (HPV and patient survival) that reported of a worse outcome of patients with HPV-associated OSCC (155). Among the above-mentioned five studies (HPV and patient survival) that reported of a worse outcome of patients with HPV-associated OSCC, mainly patients with non-OPSCC were investigated (92,96,98,110,126). An interesting study by Marklund indicated that perhaps even the localization of ‘oropharynx’ is too vague, as for neither p16+ nor HPV+ patients with oropharyngeal tumors outside the tonsils and base of the tongue could prognostic benefits be observed (53). Furthermore, in another study, the survival advantage of HPV-associated OPSCC was limited to tumors of the tonsils and base of the tongue (52). Therefore, in future, the description and separation of OPSCC should be more detailed. The reason for HPV-associated cancers having an improved long-term prognosis is still not wholly clear, although several theories have been proposed. The favorable prognosis may be based on the fact that HPV-associated carcinomas have markedly fewer genetic alterations compared with carcinomas induced through noxious agents (44), and thus, an increased sensitivity to DNA-damaging processes exists (156). This observation is also in accordance with the fact that, among patients with HPV-associated cancers, fewer smokers are observed; as the probability of genetic alterations rises with each additional pack year (13). Additionally, this hypothesis is supported by the finding that HPV+ tumors with TP53 mutations have not been associated with an improved prognosis (48,157). No conclusion can be made as to whether the improved prognosis for surgically treated patients is invalid because of the small number of cases. Just as TP53 mutations can be observed less frequently in HPV-associated carcinomas (158), other relationships with specific biomarkers exist (156). This observation is also in accordance with the fact that, among patients with HPV-associated cancers, fewer smokers are observed; as the probability of genetic alterations rises with each additional pack year (13). Additionally, this hypothesis is supported by the finding that HPV+ tumors with TP53 mutations have not been associated with an improved prognosis (48,157). No conclusion can be made as to whether the improved prognosis for surgically treated patients is invalid because of the small number of cases. Just as TP53 mutations can be observed less frequently in HPV-associated carcinomas (158), other relationships with specific biomarkers have been discussed, for example, the lower expression of epidermal growth factor receptor and a rarer amplification at 11q13 (159). Furthermore, combined effects of the immune response to the virus and the tumor may be responsible; specific T-cells against HPV16 E7 protein have been detected, but their role remains unclear (160). The fact that patients with HPV-associated HNSCC rarely develop secondary tumors may contribute to improved survival rates (161), although it should be noted that patients affected by HPV-associated cancers are mostly younger (13,32,33,54). However, some other studies refute this thesis, claiming the improved prognosis observed in HPV+ patients is independent of their tobacco consumption (26). Regarding comorbidities, for patients with HPV+ OPSCC and, in general, HNSCC with lower comorbidities, a significantly improved long-term survival has been observed (104). In contrast, for patients with HPV-associated OPSCC/HNSCC with higher comorbidities, no prognostic benefit has been recognized (104). This suggests that the
health status of the patients should be considered (104). With respect to the detection methods, as explained above, the examination of HPV status with a combined method utilizing p16 IHC, PCR and chip analysis may be advantageous (153). However, the molecular mechanisms that underlie the presumed survival advantage have not yet been sufficiently studied. Thus, no definitive recommendations can be made for HPV detection, and further studies are still needed. Additional tests, including for TP53 mutations, amplification at 11q13, and E6 and E7 PCR may be helpful (154). In addition to the previously described factors that may influence the prognostic relevance of HPV-associated HNSCC, one important question is whether the supposed improved outcome is independent of the treatment method employed. An improved response to chemotherapy and radiotherapy has been discussed, but even for this there is disagreement; p16+ patients often underwent a more aggressive adjuvant therapy, because of their more frequent lymph node involvement and lower rate of comorbidities (14). This raises the question as to whether the prognostic benefits are attributable to the more intense treatment and not to the less aggressive tumors (14). Baumeister et al (14) also indicated that the most common causes of mortality in patients with HPV-associated carcinomas were distant metastases and the relatively late tumor onset; thus a 10-year monitoring period was suggested to be advantageous.

Regarding published studies on HPV infection in HNSCC, it should be noted that the detection methods and study cohorts may provide bias. Furthermore, the role of HPV infection in OSCC is of minor relevance, and only a minority of cases are HPV+. In OPSCC, and particularly in cancers of the tonsils and base of the tongue, HPV infection and positivity for the surrogate marker p16 may be of high relevance for survival. Therefore, p16-positivity is included in the recent World Health organization TNM classification for OPSCC. In the next few years, the predicted rising numbers of vaccination against HPV infection may serve a notable role regarding the incidence of HPV+ cancers. For details see also ‘Bischof C: PhD Thesis, in prep’.

Acknowledgements

The authors would like to thank Dr Lynne Stecher for providing support and helpful contributions to this manuscript.

Funding

No funding was received.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

CG, CB, LS, KDW and AK designed the study. CG, CB, LS, KDW and AK conducted the study. CG and CB collected the data. CG, LS and CB analyzed the data. CG and CB interpreted the data. CG, CB, LS, KDW and AK drafted the manuscript. CG, CB, LS, KDW and AK wrote the manuscript. CG, CB, LS, KDW and AK approved the final version of the manuscript. CG, CB, LS, KDW and AK take responsibility for the integrity of the data analysis.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer. J Int Cancer 127: 2893-2917, 2010.
2. Kaatsch P, Spix C, Katalinic A, Hentschel S, Luttmann S and Stegmaier C: Cancer in Germany 2011/2012. Robert Koch Institute and the Society of Epidemiological Cancer Registries in Germany. Robert-Koch-Institut, Berlin, 2015 (In German).
3. Licitira L., Zigon G, Gatta G, Sanchez MJ and Berrino F: Human papillomavirus in HNSCC: A European epidemiologic perspective. Hematol Oncol Clin North Am 22: 1143-1153, vii-viii, 2008.
4. Chaturvedi AK, Engels EA, Anderson WF and Gillison ML: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26: 612-619, 2008.
5. Sørstrøm KJ, Pyrhönen S, Sørstrøm SM and Lamberg MA: Immunohistochemical demonstration of human papilloma virus (HPV) antigens in oral squamous cell lesions. Br J Oral Surg 21: 147-153, 1983.
6. World Health Organization; International Agency for Research on Cancer: Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 90. IARC, Lyon, pp1-636, 2007.
7. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, et al: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29: 4294–4301, 2011.
8. Mehanna H, Beech T, Nicholson T, El-Hariry I, Conkey C, Paler V and Roberts S: Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck 35: 747-755, 2013.
9. Stein AP, Saha S, Yu M, Kimple RJ and Lambert PF: Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time. Chem Res Toxicol 27: 462-469, 2014.
10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J and Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med 6: e1000100, 2009.
11. Moher D, Liberati A, Tetzlaff J and Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264-269, 2009.
12. Al-Swailah IN, Huang CC, Fang FM, Chuang HC, Huang HY, Luo SD, Chen CH, Chen CM and Chien CY: Prognostic impact of p16, p53, epidermal growth factor receptor, and human papillomavirus in oropharyngeal cancer in a betel nut-chewing area. Arch Otalaryngol Head Neck Surg 136: 502-508, 2010.
13. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DJ, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363: 24-35, 2010.
14. Baumeister P, Retzl M, Welz C, Becker S, Betz C and Harréus U: Surgically treated oropharyngeal cancer: Risk factors and tumor characteristics. J Cancer Res Clin Oncol 140: 1011-1019, 2014.
African Americans with...
58. Human papillomavirus in situ hybridization with or without p16 immunohistochemistry alone is a better prognosticator in tonsillar cancer than human papillomavirus in situ hybridization with or without p16 immunohistochemistry. Acta Otolaryngol 133: 297-304, 2013.
82. UKO OC, Flanagan JJ, Ma XJ, Luo Y, Thorstad WL and Lewis JS Jr: High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient survival in oropharyngeal carcinoma. Am J Surg Pathol 35: 1343-1350, 2011.

83. UKO OC, Pritchett CV, Lewis JE, Weaver AL, Smith DI and Moore EJ: Human papillomavirus-associated oropharyngeal squamous cell carcinomas: Primary tumor burden and survival in cervicalgal patients. Ann Otol Rhinol Laryngol 118: 368-373, 2009.

84. Ward MJ, Mellows T, Harris S, Webb A, Patel NN, Cox HJ, Piper K, Ottensmeier CH, Thomas GJ and King EV: Staging and treatment of oropharyngeal cancer in the human papillomavirus era. Head Neck 37: 1002-1015, 2015.

85. Wati MT, Pourmand N, Tachibana T, Kelley SM, Mellows T, Riley C, Harris S, Suchak K, Webb A, Hampion C, Patel NN, Randall CJ, et al: Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer 110: 489-500, 2014.

86. Weinberger PM, Merkley MA, Khichi SS, Lee JR, Pysrry A, Jackson LL and Dynan WS: Human papillomavirus-active head and neck cancer and ethnic health disparities. Laryngoscope 120: 1531-1537, 2010.

87. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, et al: Molecular characterization identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24: 736-747, 2006.

88. Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, et al: Cheopselo: a strategy for patient reservation in advanced oropharynx cancer: Response and survival positively associated with HPV16 copy number. J Clin Oncol 26: 3138-3146, 2008.

89. Worsham MJ, Stephen JK, Chen KM, Mahan M, Schwartz V, Havard S and Divine G: Improved survival with HPV among African Americans with head and neck cancer. Cancer Research 68: 2079-2087, 2008.

90. Young RJ, Rischion D, Fisher R, McArthur GA, Fox SB, Peters LJ, Corry J, Lim A, Waldeck K and Solomon B: Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 20: 1230-1237, 2011.

91. Chen YW, Kao SY and Yang MH: Analysis of p16(INK4A) expression in oral squamous cell carcinomas in Taiwan: Prognostic correlation without relevance to betel quid consumption. J Surg Oncol 106: 149-154, 2012.

92. Duray A, Desgamps G, Decaestecker C, Remmelink M, Sirtaine N, Lechien J, Ernoux-Neufcoeur P, Bletard P, Nemja D, Depuydt CE, et al: Human papillomavirus DNA strongly correlates with poorer prognosis in oral cavity carcinoma. Laryngoscope 122: 1558-1565, 2012.

93. Elango KJ, Suresh A, Erode EM, Suresh A, Subhadradevi L, Revadkar HN, Iyer SK, Iyer SK and Kuriakose MA: Role of human papilloma virus (HPV) infections in oral squamous cell carcinomas, a comprehensive evaluation of human papillomavirus positive head and neck squamous cell carcinoma in the south Indian population. Oral Oncol 49: 89-91, 2013.

94. Gröbe A, Handke H, Kluwe L, Schellhuber M, Tribius S, Pohlenz P, Claudio T, Böhm T, Simon R, Sauter G, Heiland M and Brosch M: Human papillomavirus infection and clinical outcomes. J Clin Virol 57: 331-337, 2013.

95. Gröbe A, Haken K, Hluwe L, Schellhuber M, Tribius S, Pohlenz P, Clauditus T, Grob T, Simon R, Sauter G, Heiland M and Brosch M: Human papillomavirus DNA strongly correlates with poor prognosis in oral cavity carcinoma. Laryngoscope 122: 1558-1565, 2012.

96. Hong SC, Faber SG, Wang HM, Huang SF, Lin CY, Fan KH, Wang HM, Huang SF, et al: Human papillomavirus 16 infection in advanced oral cancer patients is related to an increased risk of distant metastases and poor survival. Plast Reconstr Surg 126: e4067, 2012.

97. Hoffmann M, Gürögü T, Gottschlich S, Lohrey C, Rittgen W, Ambrosch P, Schuster M, Ewertz M, Wichmann C, Bernards C, Schlegel M and Wolfensberger M: Is the expression of HPV16 E6/E7 oncoproteins an independent predictor in oral squamous cell carcinoma? J Oral Pathol Med 42: 767-776, 2014.

98. Higashikawa K and Kamata N: Human papillomavirus-16 in oral squamous cell carcinoma; Clinical correlates and 5-year survival. Br J Oral Maxillofac Surg 45: 116-122, 2007.

99. Kozomara R, Jović N, Magić Z, Branković ‑Magić M and Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, et al: Molecular characterization identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24: 736-747, 2006.

100. Nasr-El-Din A, Esmaili A, Kang CH, Yoon IH, Lee YS, Lee HH, Kim SM, Seo YS, Lee JG, et al: Lack of evidence of human papillomavirus-induced squamous cell carcinomas of the oral cavity in southern Germany. Oral Oncol 49: 937-942, 2013.

101. Sugiyama M, Bhawal UK, Kawamura M, Ishioka Y, Shigeishi H, Higashikawa K and Kamata N: Human papillomavirus-16 in oral squamous cell carcinoma; Clinical correlates and 5-year survival. Br J Oral Maxillofac Surg 45: 116-122, 2007.

102. Zhao D, Xu QG, Chen XM and Fan MW: Human papillomavirus as an independent predictor in oral squamous cell cancer. Int J Oral Sci 1: 119-125, 2009.

103. Ankerla AD, Smith RV, Burk RD, Prystowsky MB, Sarta C and Schlecht NF: Comorbidity, human papillomavirus infection and head and neck cancer survival in an ethnically diverse population. Oral Oncol 49: 911-917, 2013.

104. Annetz K, Rosenquist K, Andersson G, Jacobsson H, Hansson BG and Wennerberg J: High-risk HPV and survival in patients with oral and oropharyngeal squamous cell carcinoma - 5-year survival analysis of a population-based study. Acta Oncologica 134: 843-851, 2014.

105. Badaracco G, Rizzo C, Mafera B, Pichi B, Giannarelli D, Rahimi SS, Vigili MG and Vemuri A: Molecular analyses and prognostic relevance of HPV in head and neck tumours. Oncol Rep 17: 931-937, 2007.

106. Báez A, Almodóvar JI, Cantor A, Celestin F, Cruz-Cruz L, Fonseca S, Trindad-Pinedo J and Vega W: High frequency of HPV16-associated head and neck squamous cell carcinoma in the Puerto Rican population. Head Neck 26: 778-784, 2004.

107. Deng Z, Hasegawa M, Aoki K, Matayoshi S, Kiyuna A, Yamashita Y, Uehara T, Agena S, Maeda H, Xie M, et al: A comprehensive evaluation of human papillomavirus positive status and p16INK4a overexpression as a prognostic biomarker in head and neck squamous cell carcinoma. J Clin Oncol 25: 67-76, 2014.

108. Deng Z, Hasegawa M, Yamashita Y, Matayoshi S, Kiyuna A, Agena S, Uehara T, Maeda H and Suzuki M: Prognostic value of human papillomavirus and squamous cell carcinoma antigen in head and neck squamous cell carcinoma. Cancer Sci 103: 2127-2134, 2012.

109. Duray A, Desgamps G, Decaestecker C, Sirtaine N, Gilles A, Kuhlidi M, Chantarin G, Depuydt PE, Delvenne P and Saussez S: Human papillomavirus predicts the outcome following concomitant chemoradiation therapy in patients with head and neck squamous cell carcinomas. Cancer 120: 594-601, 2014.

110. Fischer CA, Zlobec I, Green E, Probst S, Storck C, Lugli A, Tornillo L, Wolfensberger M and Terracciano LM: Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma independent of the treatment modality? Int J Cancer 126: 1256-1262, 2010.

111. Gavd M, Pellet S, Pozzetto B, Oriol M, Dunmollow JD, Timoshenko AP, Martin C and Prades JM: Human papillomavirus and head and neck squamous cell carcinomas in the South-East of France: Prevalence, viral expression, and prognostic implications. Acta Oncologica 133: 538-543, 2013.

112. Hoffmann M, Gürögü T, Gottschlich S, Lohrey C, Rittgen W, Ambrosch P, Schwarz E and Kahn T: Human papillomavirus infections in head and neck cancer: 8 year-survival-analysis of 73 patients. Cancer Lett 212: 2127-2134, 2004.

113. Iglesias-Beltran JA, González-Kidd JO, Kim MS and Webb AL: Impact of betel use on HPV status and p16INK4a overexpression as a prognostic biomarker in head and neck squamous cell carcinoma. Oral Oncol 49: 1236-1240, 2013.
1.  Laco J, Nekvindova J, Novakova V, Celakovsky P, Dolezalova H, Tucek L, Vosmikova H, Vosmik M, Neskdulova T, Cermaková E, et al.: Biologic importance and prognostic significance of selected clinicopathological parameters in patients with oral and oropharyngeal squamous cell carcinoma, with emphasis on smoking, protein p16 (INK4a) expression, and HPV status. Neoplasma 59: 398-408, 2012.

2.  Lassen P, Eriksen JG, Krogdahl A, Therkildsen MH, Ulhøi BP, Overgaard M, Specht L, Andersen E, Johansen J, Andersen LM, for the Danish Head and Neck Cancer group (DAHANCA): The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol 100: 49-55, 2011.

3.  Löffler RJ, de Vries JF, Koifman RJ, Koifman S, Curado MP, Michalau-Juárez P, Figueredo DL, Saggiore FP, de Carvalho MB, et al.: Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection. Cancer Causes Control 25: 461-471, 2014.

4.  Lukesova E, Boucek J, Rotnaglova E, Salakova M, Kloslabova E, Grega M, Eckschläger T, Rihova B, Prochazka B, Klovak J, et al.: High level of Tregs is a positive prognostic marker in patients with HPV-positive oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med 38: 142-149, 2009.

5.  Rades D, Seibold ND, Gebhard MP, Noack F, Schild SE and Thorns C: Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlenther Onkol 187: 626-632, 2011.

6.  Rautava J, Korpaskoski J, Syrjänen K, Grenman R and Syrjänen S: HPV genotypes and their prognostic significance in head and neck squamous cell carcinomas. J Clin Virol 53: 116-120, 2012.

7.  Ritchie JM, Smith EM, Summersgill KF, Scott JC, et al.: Molecular and Clinical Oncology 10: 17-28, 2019.

8.  Sivars L, Näsman A, Tertipis N, Vlastos A, Ramqvist T, and Kim MS: Characteristics and prognostic implications of high-risk HPV-associated hypopharyngeal cancers. PLoS One 8: e78718, 2013.

9.  Wee D, Koopmann M and Rudack C: Prevalence and impact on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 27: 992-1998, 2009.

10.  Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alers R, et al.: Human papillomavirus (HPV) infection as a prognostic factor in patients with the oral cavity and oropharynx. Int J Cancer 104: 336-344, 2003.

11.  Löffler RJ, de Vries JF, Koifman RJ, Koifman S, Curado MP, Michalau-Juárez P, Figueredo DL, Saggiore FP, de Carvalho MB, et al.: Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection. Cancer Causes Control 25: 461-471, 2014.

12.  Rittá M, De Andrea M, Mondini M, Mazibrada J, Giordano C, Pecorari G, Garzaro M, Landolfo V, Schena M, Chiusa L, et al.: Human papillomavirus and p53 expression in patients with oral and oropharyngeal squamous cell carcinomas with favorable outcome. J Natl Cancer Inst 2014: 269-276, 2012.

13.  Thibaudreau E, Fortin B, Coutlée F, Nguyen-Tan P, Weng X, Audet ML, Abboud O, Guertin L, Christopoulos A, Tabet J, et al.: HPV prevalence and prognostic value in a prospective cohort of patients with locally advanced HNSCC: A single-centre experience. Int J Otolaryngol 2013: 437815, 2013.

14.  Alós L, Moyano S, Nadal A, Alobid I, Blanch JL, Ayala E, Lloveras B, Quint W, Cardesa A and Ordi J: Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome. Cancer 115: 2701-2709, 2011.

15.  Ermou-Neufcoeur P, Arafa M, Decaestecker C, Duray A, Remmelink M, Leroy X, Herfs M, Somja J, Depuydt CE, Delvenne P, et al.: Combined analysis of HPV DNA, p16, p21 and p53 to predict prognosis in patients with stage IV hypopharyngeal carcinoma. J Cancer Res Clin Oncol 137: 173-181, 2011.

16.  Fakhrly C, Westra WH, Li S, Cmelak A, Ridge JA, Pinti H, Forastiere A and Gillison ML: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100: 261-269, 2008.

17.  Friedland P, Thomas A, Naran A, Amanuel B, Griou-Jacquotte F, Carrello R, Harnett G, Meyer C and Phillips M: Human papillomavirus and gene mutations in head and neck squamous cell carcinomas. Cancer 132: 466-476, 2010.

18.  Heath S, Willis V, Alkan K, Purdie K, Harwood C, Shields P, Simcock R, Williams T and Gilbert DC: Clinically significant human papilloma virus in squamous cell carcinoma of the head and neck in UK practice. Clin Oncol (R Coll Radiol) 24: e18-23, 2012.

19.  Joo EH, Lee YS, Cho KJ, Park JO, Nam IC, Kim CS, Kim SY and Kim MS: Characteristics and prognostic implications of high-risk HPV-associated hypopharyngeal cancers. PLoS One 8: e78718, 2013.

20.  Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alers R, et al.: Human papillomavirus (HPV) infection as a prognostic factor in patients with the oral cavity and oropharynx. Int J Cancer 104: 336-344, 2003.

21.  Rittá M, De Andrea M, Mondini M, Mazibrada J, Giordano C, Pecorari G, Garzaro M, Landolfo V, Schena M, Chiusa L, et al.: Human papillomavirus and p53 expression in patients with oral and oropharyngeal squamous cell carcinomas with favorable outcome. J Natl Cancer Inst 2014: 269-276, 2012.

22.  Löffler RJ, de Vries JF, Koifman RJ, Koifman S, Curado MP, Michalau-Juárez P, Figueredo DL, Saggiore FP, de Carvalho MB, et al.: Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection. Cancer Causes Control 25: 461-471, 2014.

23.  Ritchie JM, Smith EM, Summersgill KF, Scott JC, et al.: Molecular and Clinical Oncology 10: 17-28, 2019.
151. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM and Tsao AS: Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2: 15, 2010.

152. Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, Wollum A, Sanman E, Wulf S, Lopez AD, et al: Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 311: 183-192, 2014.

153. Adelstein DI, Ridge JA, Gillison ML, Chaturvedi AK, D’Souza G, Gravitt PE, Westra W, Psysri A, Kast WM, Koutsky LA, Giuliano A, et al: Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck 31: 1393-1422, 2009.

154. Ragin CC and Taioli E: Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 121: 1813-1820, 2007.

155. Götz C, Drecoll E, Straub M, Wolff KD and Kolk A: Impact of HPV infection on oral squamous cell carcinoma. Oncotarget 7: 76704-76712, 2016.

156. Butz K, Geisen C, Ullmann A, Spitkovsky D and Hoppe-Seyler F: Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. International journal of cancer. Journal international du cancer 68: 506-513, 1996.

157. Hafkamp HC, Speel EJ, Haesevoets A, et al: A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4a and p53 in the absence of mutations in p53 exons 5-8. International journal of cancer. Journal international du cancer 107: 394-400, 2003.

158. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahrakar ML, Daniel RW, Viglione M, Symer DE, et al: Evidence for a causal association between human papillo-

159. Ragin CC, Taioli E, Weissfeld JL, White JS, Rossie KM, Modugno F and Gollin SM: 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer 95: 1432-1438, 2006.

160. Hoffmann TK, Arsov C, Schirlaw K, Bas M, Friebe-Hoffmann U, Klussmann JP, Schechenbach K, Balz V, Bier H and Whiteside TL: T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 118: 1984-1991, 2006.

161. Chaturvedi AK: Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol 6 (Suppl 1): S16-S24, 2012.

162. De Petrini M, Rittà M, Schena M, Chiusa L, Campisi P, Giordano C, Landolfo V, Pecorari G and Landolfo S: Head and neck squamous cell carcinoma: Role of the human papillo-

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.